文献速递基础与转化研究临床试验与 GCP组学、生物样本库与精准医学

基因组与转录组分析拓展精准肿瘤医学:WINTHER试验

Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial.
PubMed 文献 · Nat Med · 2019-04-22

WINTHER试验(NCT01856296)根据新鲜活检DNA测序(A组,236基因panel)或RNA表达(B组,肿瘤与正常组织比较)为患者匹配治疗。303例患者知情同意,107例(35%;A组69例,B组38例)可评估疗效。A组疾病稳定≥6个月及部分或完全缓解率为23.2%,B组为31.6%(P=0.37)。无进展生存期比值>1.5的患者比例为22.4%,未达到预设主要终点。

要点

  • DNA测序和RNA表达分析均可用于改善治疗推荐和患者结局。
  • A组疾病稳定≥6个月及部分或完全缓解率为23.2%,B组为31.6%(P=0.37)。
  • 既往治疗线数较少、体能状态较好和高匹配评分与更长的无进展生存期相关(多因素分析均P<0.05)。

核心结论

  • 基因组和转录组分析均有助于改善治疗推荐和患者结局,拓展了个体化癌症治疗。

研究设计与样本

  • WINTHER试验(NCT01856296)为前瞻性临床试验,根据新鲜活检DNA测序(A组,236基因panel)或RNA表达(肿瘤与正常组织比较)将患者导航至治疗。
  • 临床管理委员会(来自五个国家的研究者)推荐治疗,优先考虑基因组匹配;医生决定实际给予的治疗。
  • 共303例患者知情同意,107例(35%;A组69例,B组38例)可评估治疗;既往治疗中位数为三线。
  • 最常见诊断包括结肠癌、头颈癌和肺癌。

主要发现

  • 107例患者中,疾病稳定≥6个月及部分或完全缓解率为26.2%(A组23.2%;B组31.6%(P=0.37))。
  • 无进展生存期比值>1.5(WINTHER治疗 vs 既往治疗)的患者比例为22.4%,未达到预设主要终点。
  • 既往治疗线数较少、体能状态较好和高匹配评分与更长的无进展生存期相关(多因素分析均P<0.05)。
  • 匹配评分事后计算:DNA为匹配的变异数除以总变异数;RNA为表达匹配的药物排名。

关键数值与推荐

  • A组可评估患者69例,B组38例。
  • A组疾病稳定≥6个月及部分或完全缓解率为23.2%,B组为31.6%(P=0.37)。
  • 无进展生存期比值>1.5的患者比例为22.4%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Precision medicine focuses on DNA abnormalities, but not all tumors have tractable genomic alterations. The WINTHER trial ( NCT01856296 ) navigated patients to therapy on the basis of fresh biopsy-derived DNA sequencing (arm A; 236 gene panel) or RNA expression (arm B; comparing tumor to normal). The clinical management committee (investigators from five countries) recommended therapies, prioritizing genomic matches; physicians determined the therapy given. Matching scores were calculated post-hoc for each patient, according to drugs received: for DNA, the number of alterations matched divided by the total alteration number; for RNA, expression-matched drug ranks. Overall, 303 patients consented; 107 (35%; 69 in arm A and 38 in arm B) were evaluable for therapy. The median number of previous therapies was three. The most common diagnoses were colon, head and neck, and lung cancers. Among the 107 patients, the rate of stable disease ≥6 months and partial or complete response was 26.2% (arm A: 23.2%; arm B: 31.6% (P = 0.37)). The patient proportion with WINTHER versus previous therapy progression-free survival ratio of >1.5 was 22.4%, which did not meet the pre-specified primary end point. Fewer previous therapies, better performance status and higher matching score correlated with longer progression-free survival (all P < 0.05, multivariate). Our study shows that genomic and transcriptomic profiling are both useful for improving therapy recommendations and patient outcome, and expands personalized cancer treatment.

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Rodon J, Soria JC, Berger R, et al. Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial. Nat Med. 2019. PMID: 31011205. doi:10.1038/s41591-019-0424-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。